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A novel, p125FAK homologue, CADTK, has been de-
tected in neural, epithelial, or hematopoietic cells but
not in fibroblasts. We now demonstrate CADTK expres-
sion in a mesenchymal cell, rat aortic smooth muscle
cells (RSMC). Angiotensin II (Ang II) or platelet-derived
growth factor (PDGF-BB and PDGF-AA) markedly stim-
ulated CADTK tyrosine phosphorylation in RSMC but
did not affect p125FAK phosphorylation. The PDGF-de-
pendent CADTK tyrosine phosphorylation was slower
and more prolonged than that of Ang II, correlating well
with the differential effects of these agonists on cytoso-
lic calcium ([Ca21]i) signaling. An intracellular calcium
chelator inhibited both the rapid and sustained activa-
tion of CADTK by Ang II and PDGF. Extracellular cal-
cium chelation inhibited the PDGF-stimulated increase
in CADTK tyrosine phosphorylation as well as the sus-
tained (but not the early) activation by Ang II. In con-
trast, p125FAK tyrosine phosphorylation was maximal in
quiescent, adherent RSMC and was not affected by in-
cubation with EGTA. Depletion of protein kinase C ac-
tivity partially inhibited both the Ang II- and PDGF-
induced CADTK tyrosine phosphorylation. Additional
results confirm a relation between CADTK and the cy-
toskeleton. First, the tyrosine phosphorylation of paxil-
lin correlated with activation of CADTK; this increase
was inhibited by EGTA. Second, cytochalasin D blocked
the PDGF- or Ang II-stimulated tyrosine phosphoryla-
tion of CADTK, suggesting a role for the cytoskeleton in
agonist-dependent CADTK activation. Third, immuno-
fluorescence analysis of CADTK localization demon-
strated actin-like cytoskeleton staining extending into
focal contacts. These results suggest that in mesenchy-
mal cells, CADTK is localized to and activated by an
actin cytoskeleton-dependent mechanism; a mechanism
that is regulated in a calcium and protein kinase C-de-
pendent manner independently of p125FAK.
The migration and proliferation of vascular smooth muscle
cells are key events in the development of atherosclerotic le-
sions and restenosis following angioplasty (reviewed in Ref. 1).
In addition to the pivotal role these cells play in the etiology of
atherosclerosis, vascular smooth muscle cells also contribute to
the pathology of hypertension (2). Smooth muscle cells respond
to growth factors such as the polypeptide PDGFs1 (PDGF-BB
or PDGF-AA), which initiate intracellular signaling pathways
leading to either cell proliferation or migration (reviewed in
Ref. 3). Binding of PDGF to its cognate receptor tyrosine kinase
stimulates a plethora of events including activation of PI-3
kinase, Ras/Raf signaling, and phospholipase Cg (reviewed in
Ref. 4). Increasing phospholipase Cg activity further contrib-
utes to intracellular signaling by regulating cytosolic calcium
levels and protein kinase C (PKC) activity. However, despite
considerable knowledge of these initial events, the ultimate
effect of these signals on smooth muscle function remains to be
elucidated.
Angiotensin II (Ang II) is a component of the renin-angioten-
sin signaling pathway and is important for both the normal and
pathological (i.e. hypertensive) states of smooth muscle physi-
ology (reviewed in Ref. 5). Ang II is a growth factor for smooth
muscle and other cell types (6). In rat smooth muscle cells
(RSMC), Ang II signaling is mediated by the AT1 receptor, a
seven-transmembrane receptor coupled to the Gq subtype of
heterotrimeric G proteins (7). Activation of this receptor in-
creases phospholipase Cb activity, resulting in the increase of
cytosolic free calcium and protein kinase C activity (6). Ulti-
mately, the influence of PDGF or Ang II on intracellular cal-
cium homeostasis affects the regulation of vascular tone, mi-
gration, and the growth of smooth muscle cells (reviewed in
Ref. 8).
Ang II has been shown to increase protein tyrosine phospho-
rylation in smooth muscle and other cell types. This has been
variably attributed to the activation of p125FAK (9), Src (10), a
calcium/calmodulin-dependent tyrosine kinase (11), or other
unidentified tyrosine kinases (12). Recently, a calmodulin-in-
dependent, calcium-dependent tyrosine kinase (CADTK) was
purified from Ang II-activated rat liver epithelial cells (13).
Peptide sequencing, isolation of the cDNA, and deduction of the
primary amino acid sequence demonstrated that CADTK was
identical to the kinase recently identified by others and known
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as Pyk-2 (14), CAKb (15), RAFTK (16), or FAK2 (17).
CADTK contains a high degree of sequence homology to the
focal adhesion kinase (p125FAK), including conservation of a
number of potentially important tyrosine phosphorylation sites
(14). One of these, tyrosine 402, is analogous to tyrosine 397 of
p125FAK and is the primary site of autophosphorylation in this
kinase (18). Phosphorylation of this amino acid provides a
binding site for kinases containing SH2 domains such as Src
and Fyn (18), and phosphorylation of Tyr402 in RAFTK
(CADTK) results in binding of the Src family kinases Lck and
Fyn to this residue (19). Pyk-2/CADTK may be responsible for
linking Src kinase signaling to “downstream” signaling events
such as the activation of MAP kinase (20), although a link
between CADTK and MAP kinase activation is absent in rat
liver epithelial cells (13). Other studies have suggested that
CADTK may be “upstream” of the c-Jun NH2-terminal kinase
(Jnk) (13, 21) and p70 S6 kinase (22); however, the requirement
for Src in the activation of these kinases has not been
established.
The expression of CADTK/Pyk-2/Cakb/RAFTK has been
demonstrated in a number of cell types including those of
neural (14), hematopoietic (16), or epithelial origin (13). In
contrast, this kinase is not expressed in fibroblasts (15). Spe-
cifically, CADTK has been shown to be regulated in a calcium-
and PKC-dependent manner in liver epithelial (13), PC12 (14),
megakaryocytes (23), platelets (24), and B cells (25) by G pro-
tein-coupled agonists and other extracellular stimuli. Potential
targets for phosphorylation by this enzyme include the cy-
toskeletal proteins paxillin (23, 26, 27) and p130 Cas (27), and
these findings imply a role for CADTK in mediating cytoskel-
etal events. This possibility is further supported by the high
amount of CADTK sequence homology (C terminus) to the
“focal adhesion targeting” region of p125FAK (14). However, the
intracellular localization of CADTK remains to be definitively
proven, with one study reporting cell-cell contact localization
(15) and another describing “focal adhesion-like structures”
(19).
In this report, we describe the expression of CADTK in cells
of mesenchymal origin (rat aortic smooth muscle cells) and
demonstrate the regulation of CADTK by both G protein-cou-
pled stimuli (i.e. Ang II) and receptor tyrosine kinase agonists
(platelet-derived growth factors, PDGF-BB and PDGF-AA). Im-
portantly, we show that CADTK is regulated by these stimuli
independently of the highly related kinase, p125FAK and find
that this occurs in a calcium- and PKC-dependent manner.
Finally, our studies demonstrate the role for CADTK in regu-
lating cytoskeletal signaling in RSMC; CADTK is localized in
part to the actin cytoskeleton and is dependent on an intact
cytoskeleton for activation. Thus, these studies suggest that
CADTK is an important mediator of tyrosine kinase signaling
in vascular smooth muscle cells in response to stimuli such as
Ang II and PDGF.
EXPERIMENTAL PROCEDURES
Materials—PDGF-AA and PDGF-BB were purchased from Life Tech-
nologies, Inc. Ang II was obtained from Sigma and diluted in 50 mM
acetic acid. RC20H anti-Tyr(P) antibody was purchased from Transduc-
tion Laboratories and diluted 1:2500 in TBST (including 1% bovine
serum albumin) for immunoblotting experiments. Paxillin monoclonal
antibody was purchased from Transduction Laboratories. Protein A
beads were purchased from Bio-Rad and washed three times with
phosphate-buffered saline prior to use. 12-Tetradecanoyl phorbol 13-
acetate (TPA) and BAPTA-AM, were obtained from Biomol and dis-
solved in Me2SO prior to the addition to cells. RSMC were obtained
from the laboratory of Dr. Russel Ross. These cells were isolated from
thoracic aorta of male Sprague-Dawley rats (4 months old) and pre-
pared as described previously (28).
Cell Cultures—Subconfluent RSMC were maintained in Dulbecco’s
modified Eagle’s medium with 10% bovine calf serum and penicillin/
streptomycin in a humidified, 5% CO2 atmosphere. 48 h prior to exper-
iments, the medium was removed and replaced with medium lacking
bovine calf serum. Following drug treatment, cells were washed twice
with cold phosphate-buffered saline and harvested in 1 ml of immuno-
precipitation buffer (20 mM Tris, pH 7.5, 1% Triton, 10% glycerol, 137
mM NaCl, 2 mM EDTA, 5 mg/ml leupeptin, 10 nM calyculin A, 250 mM
phenylmethylsulfonyl fluoride, and 150 mM sodium vanadate). The cell
lysates were centrifuged at 12,000 3 g for 10 min, and the resultant
supernatants were transferred to clean microcentrifuge tubes.
Measurement of CADTK, p125FAK, and Paxillin Tyrosine Phospho-
rylation—The amount of CADTK, p125FAK, or paxillin tyrosine phos-
phorylation was assayed by the procedure described earlier (13, 29)
with minor modifications. CADTK was immunoprecipitated with rabbit
antisera developed against a GST-CADTK fusion protein (13). p125FAK
was immunoprecipitated with a mouse monoclonal antibody, 2A7,
kindly provided by Dr. T. Parsons (University of Virginia) or a poly-
clonal antibody, A17 (Santa Cruz). A monoclonal antibody (Transduc-
tion Laboratories) was used to immunoprecipitate paxillin. Protein
A-agarose beads were used to precipitate the CADTK and A17 immu-
nocomplexes, while protein A/G beads were used to precipitate the 2A7
and paxillin immunocomplexes. For determination of tyrosine phospho-
rylation, samples were applied to SDS-PAGE (10% acrylamide), trans-
ferred to polyvinylidene difluoride (Immobilon-P) membrane, blocked
with 1% bovine serum albumin/TBST, immunoblotted with RC20H, and
developed with enhanced chemiluminescence (ECL) reagent according
to the manufacturer’s procedure (NEN Life Science Products).
Northern Analysis—Total RNA was prepared from RSMC and rat
liver epithelial cells (WB), with Trizol® solution according to the man-
ufacturer’s protocol (Life Technologies, Inc.). RNA (30 mg) was sepa-
rated on a 12% formaldehyde-agarose gel and transferred to a Zeta-
Probe® GT blotting membrane (Bio-Rad) and probed with full-length
CADTK cDNA labeled with [32P]dCTP by random priming.
Determination of Intracellular Calcium—Ca21i was measured using
digitized video microscopy in RSMC grown on glass coverslips and
loaded with the calcium-sensitive fluorophore, Fura-2/AM, as described
previously (30).
Immunofluorescence Detection of CADTK—For immunofluorescence
microscopy, cells were grown on two-well chamber slides (Becton Dick-
inson), washed once with phosphate-buffered saline, and fixed with 4%
paraformaldehyde for 8 min. The cells were then permeabilized by
washing with 220 °C acetone twice for 30 s. Cells were then washed
three times with HBSS and blocked for nonspecific sites with 10% goat
serum in HBSS for 1 h. Upon completion of blocking, cells were washed
twice with HBSS and stained for filamentous actin using 1 mg/ml
tetramethylrhodamine isothiocyanate (TRITC) phalloidin (Sigma) or an
appropriate dilution of primary antibody in HBSS plus 10% goat serum
and incubated for 1 h at room temperature. The antisera used were
raised against a GST-CADTK fusion protein encompassing amino acids
1–80 or 680–860 of rat CADTK. The antiserum was prepared for
immunofluorescence by purification of the IgG fraction using a Protein
A-Sepharose column (Sigma) and was subsequently depleted of GST
immunoreactivity by passing over an Affi-Gel 10 column made by
coupling GST (18 mg) to this resin. The specific immunofluorescence
was blocked by preincubation of the the purified antibodies with the
immunizing GST-CADTK fusion proteins. Cells were washed exten-
sively and incubated in with a 1:500 dilution of secondary antibody
labeled with Oregon Green (Molecular Probes). Fluorescence was visu-
alized using a Zeiss Axioplan microscope under 3 60 and 3 100 objec-
tives (3 10 oculars) and photographed with Tmax 400 film.
RESULTS
Expression and Regulation of CADTK by Ang II or PDGF in
RSMC—CADTK expression was examined in RSMC by North-
ern and Western blotting analysis. Total RNA was isolated
from RSMC and subjected to Northern blot analysis using
radiolabeled rat CADTK cDNA as a probe (13). As shown in
Fig. 1A, a 4.0-kilobase transcript was found that was identical
in size to the CADTK mRNA expressed in rat liver epithelial
cell lines (GN4, WB). To confirm that CADTK protein was
expressed in RSMC, cell lysates were immunoprecipitated with
antiserum specific for CADTK and immunoblotted for CADTK
protein. Immunoblotting RSMC lysates for CADTK detected a
120-kDa protein that co-migrated on SDS-PAGE with CADTK
purified from GN4 liver epithelial cells (data not shown). The
antiserum used in these experiments was previously shown not
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to cross-react with the related kinase p125FAK (13), and
CADTK could be resolved from p125FAK on SDS-PAGE by
using lower percentage bisacrylamide gels as described earlier
(29).
The regulation of CADTK tyrosine phosphorylation (Tyr(P))
by agonists known to influence smooth muscle growth or mi-
gration was examined. CADTK Tyr(P) has been shown to in-
crease in parallel with CADTK kinase activity (Poly-Glu/Tyr
phosphorylation) (13); thus, CADTK Tyr(P) was determined as
a measure of CADTK activity. However, it should be noted that
the observed CADTK Tyr(P) measured in these studies may be
a combination of that catalyzed by CADTK (autophosphoryla-
tion) and that of a CADTK-associated kinase such as Src. Both
Src and Src family members (Lck, Fyn) have been shown to
bind CADTK (Pyk-2/RAFTK (18, 19)) and may contribute to the
phosphorylation of CADTK in cells.
Immunoprecipitation of CADTK from Ang II (1 mM)-treated
cells demonstrated a rapid increase in CADTK Tyr(P) as de-
termined by anti-phosphotyrosine (anti-Tyr(P)) immunoblot-
ting (Fig. 1B). An increase in CADTK phosphorylation was
detected as early as 30 s following the Ang II addition. This
increase peaked after approximately 3–5 min and began to
decline thereafter. PDGF-BB also stimulated a significant in-
crease in CADTK phosphorylation, although the peak of phos-
phorylation in response to this stimulus occurred later than
that observed with Ang II. Again, CADTK Tyr(P) was observed
as early as 30 s after exposure to PDGF-BB; however, the
tyrosine phosphorylation of CADTK continued to increase up to
20 min after the PDGF-BB addition and declined very slowly
thereafter (Fig. 1, B and C, and data not shown). The increase
in CADTK Tyr(P) was also accompanied by an increase in
tyrosine kinase activity as assessed by phosphorylation of poly-
Glu/Tyr in the presence of [g-32P]ATP/MgCl2 (data not shown).
PDGF-AA also stimulated an increase in CADTK Tyr(P), but
consistent with a higher number of receptors for PDGF-BB
(PDGF-b) as compared with PDGF-AA (PDGF-a) in these cells,
PDGF-BB gave a larger increase in CADTK phosphorylation
than that observed with an identical concentration (1.5 nM) of
PDGF-AA (data not shown).
p125FAK Tyrosine Phosphorylation Is Not Stimulated by Ang
II or PDGF in RSMC—The primary amino acid sequence of
CADTK contains regions of high homology to p125FAK (65%
amino acid similarity overall) (31). Because of the high degree
of similarity between these kinases, we compared the effect of
stimuli found to increase CADTK phosphorylation on the tyro-
sine phosphorylation of p125FAK in RSMC. Immunoprecipita-
tion and anti-Tyr(P) blotting of p125FAK from lysates of adher-
ent, serum-starved cells showed that p125FAK was highly
tyrosine-phosphorylated in quiescent RSMC in contrast to
CADTK, which contained little or no detectable phosphoty-
rosine under these conditions (Fig. 1, compare B and D). Incu-
bating RSMC with Ang II or PDGF-BB did not stimulate a
significant increase in p125FAK Tyr(P), even after prolonged
exposure to Ang II (10 min) or PDGF (20 min) (Fig. 1D and data
not shown). In contrast, these agonists markedly stimulated
CADTK Tyr(P) (see Fig. 1B), demonstrating that the phospho-
rylation of CADTK was regulated by these agonists independ-
ently of p125FAK in RSMC.
Calcium Chelators Inhibit CADTK but Not p125FAK Phos-
phorylation—BAPTA-AM is a cell-permeable calcium chelator
that prevents the hormonally induced rise in intracellular cal-
cium and inhibits the agonist-stimulated CADTK/Pyk-2 activ-
ity in PC12 or rat liver epithelial cells (14). CADTK is not
tyrosine phosphorylation (a-P-TYR) or p125FAK protein (a-FAK) was
measured by SDS-PAGE/immunoblotting.
FIG. 1. CADTK expression and regulation by Ang II or
PDGF-BB in RSMC. A, total RNA was isolated from RSMC or rat liver
epithelial cells (WB, GN4), as described under “Experimental Proce-
dures.” The extracted RNA was electrophoresed on a 12% formaldehyde
agarose gel, electrophoretically transferred to nitrocellulose membrane,
and incubated with a radiolabeled (32P) oligonucleotide probe comple-
mentary to full-length CADTK. B, serum-starved RSMC were treated
with either 1.5 nM PDGF-BB or 1 mM Ang II for the amount of time
indicated. RSMC were harvested in lysis buffer (1 ml), CADTK was
immunoprecipitated, and the amount of tyrosine phosphorylation (a-P-
TYR) or CADTK protein (a-CADTK) was determined by SDS-PAGE/
immunoblotting as described under “Experimental Procedures.” C,
RSMC were prepared as in B and were incubated with PDGF-BB (1.5
nM) for the amount of time indicated. CADTK was immunoprecipitated,
and the Tyr(P) was determined as described above (B). D, using a
monoclonal antibody to p125FAK (2A7), p125FAK was immunoprecipi-
tated from an aliquot of the lysates prepared in B, and the amount of
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activated by calcium or calmodulin in vitro (29), suggesting
that CADTK is regulated by a calcium-dependent event in
intact cells. The calcium dependence of agonist-stimulated
CADTK phosphorylation in RSMC was examined by incubat-
ing cells with BAPTA-AM (50 mM), or EGTA (2 mM), a non-cell-
permeable calcium chelator. As shown in Fig. 2A, treatment
with BAPTA-AM or EGTA inhibited both the PDGF-BB and
Ang II-stimulated increase in CADTK Tyr(P). However, incu-
bating RSMC with EGTA did not inhibit the initial, rapid
increase in Ang II-stimulated CADTK (30–90 s) phosphoryla-
tion but significantly reduced the latter phase of tyrosine phos-
phorylation (10–20 min) (Fig. 2B), suggesting that at later
times, influx of calcium from extracellular sources played a
more important role in the activation of CADTK. In compari-
son, the cell-permeable chelator BAPTA-AM inhibited the early
Ang II-dependent CADTK phosphorylation (see Fig. 2A), dem-
onstrating the reliance of this initial event upon an intracellu-
lar calcium signal.
With PDGF-BB as a stimulus, EGTA inhibited both the
initial and the latter phases of CADTK phosphorylation (Fig.
2C), indicating that both intracellular and extracellular
sources of calcium were important for activation of CADTK in
response to this agonist. The importance of extracellular cal-
cium was further supported by incubation of RSMC in calcium-
free media; this treatment inhibited the tyrosine phosphoryla-
tion of CADTK in response to PDGF or Ang II (10 min).
Incubation of RSMC with the calcium ionophore ionomycin (1
mM, 10 min) increased CADTK phosphorylation, demonstrating
the efficacy of a calcium signal alone to increase CADTK phos-
phorylation (data not shown).
In comparison, incubation with EGTA did not affect the
tyrosine phosphorylation of p125FAK (Fig. 2D), demonstrating
that the calcium-dependent regulation of CADTK occurred in-
dependently of p125FAK in RSMC.
CADTK Regulation: Comparison of Chelators on Calcium
Signaling in RSMC—PDGF and Ang II have been shown to
have qualitatively different effects on the source, duration, and
level of elevation of cytosolic free calcium in vascular smooth
muscle cells (32). To attempt to explain the differential effects
of the calcium chelators on CADTK phosphorylation, calcium
imaging was performed by incubating RSMC with a cell-per-
meable fluorescent indicator, Fura-2/AM, and the levels of
PDGF- and Ang II-stimulated cytosolic free calcium ([Ca21]i)
were measured as described earlier (30). In serum-starved
RSMC, Ang II stimulated a sharp increase in [Ca21]i, which
peaked after 15–30 s and declined to approximately 50% of the
maximum level within 1–2 min (Fig. 3A). In contrast, PDGF
increased [Ca21]i more slowly (maximum at 60–90 s), and the
[Ca21]i remained elevated for at least 10 min (Fig. 3B). As
expected, pretreatment with BAPTA-AM abolished the initial
PDGF or Ang II-stimulated peak of [Ca21]i (data not shown).
Incubation with the extracellular calcium chelator, EGTA, did
not inhibit the initial Ang II-stimulated increase in [Ca21]i but
eliminated the slower prolonged elevation of [Ca21]i (Fig. 3A).
With PDGF as a stimulus, EGTA partially inhibited the initial
increase and completely eliminated the sustained increase in
[Ca21]i (Fig. 3B), indicating that the slower accumulation of
[Ca21]i was primarily due to influx from extracellular stores.
These findings correlated well with the effect of these chelators
on CADTK Tyr(P) (See Fig. 2, B and C), suggesting that the
distinct pattern of CADTK activation by these stimuli may be
through the regulation of both intracellular and extracellular
calcium signaling.
PKC-dependent Activation of CADTK Phosphorylation in
RSMC—Phorbol esters (TPA) stimulate PKC and CADTK/
Pyk-2 activity in both rat epithelial and PC12 cells (13, 14). To
investigate whether PKC was required for the PDGF- or Ang
II-dependent phosphorylation of CADTK in RSMC, cells were
chronically exposed to TPA (1 mM, 24 h) to deplete cells of
TPA-sensitive isoforms of PKC. Acute incubation of non PKC-
depleted cells with TPA (5 min) resulted in an increase in
CADTK Tyr(P) similar in magnitude to that found with Ang II
or PDGF (Fig. 4). After chronic exposure to TPA (1 mM, 24 h), a
brief treatment with TPA (100 nM, 5 min) did not increase
CADTK Tyr(P), demonstrating the effectiveness of this treat-
ment to ablate PKC activity. This protocol also eliminated the
PKC-dependent activation of MAP kinase in these cells (data
not shown). As shown in Fig. 4, down-regulation of PKC sig-
nificantly inhibited both the Ang II- and PDGF-BB-stimulated
increase in CADTK Tyr(P) (Fig. 4).
Regulation of Paxillin Phosphorylation in RSMC—The cy-
FIG. 2. The effect of calcium chelators on CADTK and p125FAK
phosphorylation. A, serum-starved RSMC were treated with carrier
(Me2SO), EGTA (2 mM, 10 min), or BAPTA-AM (50 mM, 15 min) prior to
incubation with 1.5 nM PDGF-BB or 1 mM Ang II. After 5 min, the cells
were harvested in lysis buffer, and the amount of CADTK Tyr(P)
(a-P-TYR) or CADTK protein (a-CADTK) was measured as described
above. B, serum-starved RSMC were incubated with or without EGTA
(2 mM, 10 min) prior to incubation with Ang II (1 mM) for the amount of
time indicated. Cells were harvested in lysis buffer, and CADTK was
immunoprecipitated and immunoblotted for Tyr(P) as described earlier.
C, cells were treated with EGTA as in B and then incubated with
PDGF-BB (1.5 nM) for the amount of time indicated, and the amount of
CADTK Tyr(P) was determined. D, RSMC were treated and harvested
as in A, and p125FAK was immunoprecipitated using a monoclonal
antibody (2A7) and immunoblotted for anti-phosphotyrosine as de-
scribed above.
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toskeletal protein paxillin has been shown to be phosphoryl-
ated in response to Ang II and PDGF in smooth muscle cells,
presumably through the regulation of p125FAK (9, 33, 34). Since
our studies suggested that Ang II and PDGF activated CADTK,
but not p125FAK, we examined the ability of these agonists to
affect paxillin tyrosine phosphorylation. Immunoblotting for
anti-Tyr(P) immunoblotting demonstrated that treatment of
RSMC with Ang II or PDGF-BB stimulated a significant in-
crease in paxillin tyrosine phosphorylation over that found in
quiescent cells (Fig. 5). The PDGF-stimulated increase in pax-
illin Tyr(P) was strongly inhibited by EGTA, whereas the Ang
II-stimulated increase was inhibited to a lesser extent by this
chelator; these results were consistent with a weaker effect of
EGTA on Ang-dependent CADTK activation (Fig. 5). Similar
results were also found with BAPTA-AM; however, in some
experiments we observed partial inhibition of p125FAK phos-
phorylation by this compound (data not shown). We therefore
used EGTA, which inhibited CADTK, but not p125FAK in these
cells. As shown in Fig. 5, the ability of EGTA to prevent the
PDGF-stimulated paxillin phosphorylation in response to
PDGF was greater than that observed with Ang II and corre-
lated with the stronger inhibitory effect of this compound on
the PDGF-stimulated increase in CADTK activity. These ex-
periments demonstrated that the changes in paxillin Tyr(P)
correlated with the ability of compounds to increase (PDGF or
Ang II) or decrease (EGTA) CADTK Tyr(P) but not p125FAK
Tyr(P) in these cells.
Cytochalasin D Treatment Prevents CADTK Activation—The
carboxyl-terminal portion of CADTK contains high homology to
the focal adhesion targeting domain of p125FAK (14), suggest-
ing that CADTK may be involved in focal adhesion and cy-
toskeletal signaling. This hypothesis has been further sup-
ported by recent studies demonstrating coimmunopre-
cipitation of CADTK with the cytoskeletal protein paxillin or
with p130 Cas (26, 27). To investigate whether activation of
CADTK required an intact cytoskeleton, cells were incubated
briefly (10 min) with cytochalasin D (1 mM) prior to stimulation
by various agonists. As shown in Fig. 6A, pretreatment with
cytochalasin D prevented the increase in CADTK Tyr(P) stim-
ulated by PDGF, Ang II, TPA, or ionomycin treatment (Fig. 6
and data not shown). Cytochalasin D did not inhibit CADTK
Tyr(P) stimulated by the tyrosine phosphatase inhibitor per-
vanadate, nor was the recovery of CADTK protein compro-
mised by cytochalasin D treatment (Fig. 6B).
CADTK Localizes to the Focal Adhesions and the Actin Cy-
toskeleton—To examine the relation of CADTK to cytoskeletal
signaling, we examined the intracellular localization of CADTK
by immunofluorescence. Serum-starved RSMC were plated on
glass coverslips and fixed with paraformaldehyde, and CADTK
was detected by incubation with the immunospecific antibodies
as described under “Experimental Procedures.” Using two in-
dependent polyclonal antibodies raised against different re-
gions of CADTK (amino acids 1–80 or 680–860 of rat CADTK),
CADTK protein staining was found along actin microfilament-
like structures that extended into focal adhesions (Fig. 7A).
This filamentous-like staining co-localized in RSMC with rho-
damine-conjugated phalloidin, indicating that these structures
were actin filaments (Fig. 7, B and C). This is clearly a different
staining pattern from p125FAK and vinculin, which are densely
concentrated around focal adhesion contacts in multiple cell
types (35).
FIG. 3. Regulation of Ca21i by Ang II or PDGF. Changes in
cytosolic free calcium ([Ca21]) were measured in serum-starved RSMC
immediately following exposure to Ang II (1 mM) (A) or PDGF-BB (1.5
nM) (B) as described under “Experimental Procedures.” [Ca21]i was
monitored using digitized videomicroscopy with Fura-2/AM as the flu-
orescent indicator. Ang II and PDGF were added at time 0, and EGTA
(2 mM), when present, was added 10 min prior to agonist stimulation.
The data presented are the average 340/380-nm ratio values obtained
from single microscope fields containing an average of nine cells each.
Results presented are representative of three or four independent ex-
periments performed for each condition examined.
FIG. 4. CADTK Tyr(P) in PKC-depleted cells. Serum-starved
RSMC were untreated (2TPA) or treated with TPA (1TPA, 1 mM, 24 h)
prior to incubation with 100 nM TPA, 1 mM Ang II, or 1.5 nM PDGF-BB
for 5 min. Cells were harvested in cell lysis buffer, and the amount of
CADTK Tyr(P) was determined as described above.
FIG. 5. Paxillin phosphorylation in response to PDGF and Ang
II; inhibition by EGTA. Serum-starved RSMC were treated as shown:
control (lane 1); 1 mM Ang II (lane 2); 2 mM EGTA, 1 mM Ang II (lane 3);
1.5 nM PDGF (lane 4); and 2 mM EGTA, 1.5 nM PDGF (lane 5). Cells
were harvested in lysis buffer, and paxillin was immunoprecipitated
with a monoclonal antibody (Transduction Laboratories). Immunoblots
were developed using an anti-Tyr(P) (RC20H) or anti-paxillin (a-paxil-
lin) antibody, and after the addition of the ECL reagents, the membrane
was exposed to film. A representative exposure is shown.
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DISCUSSION
PDGF and Ang II are potent physiological mediators of vas-
cular smooth muscle cell function, and many of the actions of
these stimuli are likely to be mediated through increases in
either calcium or PKC signaling. In this report, we demon-
strate that the recently identified calcium- and PKC-activated
tyrosine kinase, CADTK, is a likely candidate to mediate signal
transduction by these stimuli in RSMC. This study confirms
that both calcium and PKC are essential yet independent ac-
tivators of CADTK phosphorylation. In addition, our results
illustrate the importance of extracellular calcium in regulating
CADTK in response to some agonists. The extended activation
of CADTK by PDGF correlated well with the influence of this
agonist on the influx of calcium from extracellular sources.
Activation by PDGF was more sensitive to the extracellular
calcium chelator EGTA than Ang II and supported earlier
studies demonstrating the qualitatively different effects of
these stimuli on calcium signaling (32).
The calcium chelators BAPTA-AM and EGTA did not com-
pletely inhibit the activation of CADTK by PDGF or Ang II,
suggesting that an additional signal was required. Our studies
suggest that this signal may be PKC. Down-regulation of PKC
inhibited CADTK activation but did not compromise the ability
of these agonists (e.g. PDGF, Ang II) to stimulate an increase in
[Ca21]i, indicating that the release of calcium from intracellu-
lar stores or influx from extracellular sources was not impaired
by this treatment.2 Depletion of both PKC activity and calcium
signaling (using calcium-free media) further reduced the acti-
vation of CADTK by Ang II,3 supporting the hypothesis that
calcium and PKC are independent and potentially additive
activators of CADTK. However, since calcium does not activate
CADTK in vitro, the mechanism by which this and PKC in-
crease CADTK activity in vivo remains to be elucidated; our
results suggest that this is mediated through a cytoskeleton-
dependent mechanism (see below).
We find that agonist-dependent phosphorylation of CADTK
occurs independently of the highly homologous focal adhesion
kinase, p125FAK, in RSMC. These observations differ from pre-
vious studies in vascular smooth muscle cells that showed Ang
II- and PDGF-stimulated p125FAK tyrosine phosphorylation (9,
34, 36). In response to Ang II, Polte et al. (36) found approxi-
mately a 4-fold increase in p125FAK Tyr(P), whereas a 50%
increase in phosphorylation was observed by Turner et al. (9).
In our studies, we occasionally observed small changes in
p125FAK phosphorylation in response to Ang II or PDGF; how-
ever, these variations were minor relative to the large increase
in CADTK Tyr(P) observed in these samples. The cause for the
discrepancies between our results and the 4-fold difference of
Polte et al. is difficult to ascertain and may represent differ-
ences in experimental conditions or antisera used in these
studies. In one study, the antisera used to study p125FAK was
raised against the COOH-terminal 150 amino acid residues of
mouse p125FAK (36), an area of high sequence homology to rat
CADTK. Thus, some of the increased phosphorylation attrib-
uted to p125FAK may be a consequence of antibody cross-pre-
cipitation to both p125FAK and CADTK, whereas the 50% in-
crease observed by Turner et al. (9) is probably within the
range of experimental variation.
Ang II and PDGF have also been reported to increase the
tyrosine phosphorylation of paxillin, presumably through the
regulation of p125FAK in smooth muscle cells (9, 33, 34). Al-
though paxillin is a substrate for p125FAK phosphorylation in
2 P. Diliberto, unpublished observations.
3 Y. He, unpublished observations.
FIG. 6. The effect of cytochalasin D on CADTK Tyr(P). A, RSMC
were prepared as described above and treated with carrier (Me2SO,
lanes 1–5) or cytochalasin D (10 mM, 10 min, lanes 6–10) prior to the
addition of the following stimuli. Lanes 1 and 6, no addition; lanes 2 and
7, 1.5 nM PDGF (10 min), lanes 3 and 8, 1 mM Ang II (3 min); lanes 4 and
9, 100 nM TPA (10 min); lanes 5 and 10, pervanadate (100 mM, 10 min).
CADTK was immunoprecipitated, and the amount of CADTK Tyr(P)
was determined by immunoblotting as above. B, the remainder of the
lysates from A were immunoprecipitated and immunoblotted, and the
amount of CADTK was visualized by ECL as described earlier.
FIG. 7. Immunolocalization of CADTK in RSMC. RSMC were
grown on glass coverslips, serum-starved, fixed, and permeabilized for
immunostaining as described under “Experimental Procedures.”
CADTK protein was detected by immunostaining with a fluorescein
isothiocyanate analog coupled to a a-rabbit secondary antibody. A,
localization of CADTK to focal adhesions and actin stress fibers in
RSMC (3 60 magnification). B and C, co-localization of CADTK on actin
filaments. B, RSMC were stained for CADTK (3 100 magnification) as
described in A. C, RSMC were co-stained for CADTK as described in A
and were stained for actin with rhodamine-conjugated phalloidin (2
mg/ml) for 30 min at room temperature (3 100 magnification).
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vitro, in a previous report the Ang II-stimulated increase in
paxillin phosphorylation did not correlate well with the effects
of these stimuli on p125FAK (9), suggesting that additional
kinases might contribute to this event. Recently, CADTK has
been shown to co-immunoprecipitate with and to preferentially
phosphorylate paxillin in some cells (26, 27). In RSMC, we also
find that CADTK and paxillin co-immunoprecipitate4 and find
that the agonist-stimulated increase in paxillin phosphoryla-
tion correlates well with the effects of these stimuli on CADTK
phosphorylation. Paxillin was observed to be weakly phospho-
rylated in unstimulated cells, suggesting that p125FAK contrib-
utes to the basal levels of paxillin phosphorylation. In compar-
ison, the stimulated increase in paxillin phosphorylation
paralleled the increase in CADTK activity and was inhibited by
EGTA, which inhibited the agonist-stimulated CADTK activity
but not p125FAK. Prior to the discovery of CADTK, Leduc and
Meloche (33) also reported that paxillin was phosphorylated in
a calcium-dependent manner in smooth muscle cells. Our stud-
ies are consistent with these earlier studies and suggest that
CADTK contributes to the stimulated (calcium- and PKC-de-
pendent) increase in paxillin Tyr(P), whereas the basal levels of
paxillin phosphorylation may be mediated by p125FAK in ad-
herent RSMC. However, although the increase in paxillin
Tyr(P) correlates with an increase in CADTK activity, the
possibility that this phosphorylation is catalyzed by a CADTK-
associated kinase cannot be excluded. Both Src and Src family
member tyrosine kinases (Lck, Fyn) directly associate with
CADTK (Pyk-2/RAFTK (18, 19)) and could potentially contrib-
ute to this event.
We also provide evidence illustrating the importance of
CADTK cytoskeletal interactions. Agonist-dependent activa-
tion of CADTK was blocked by disruption of the actin cytoskel-
eton with cytochalasin D, consistent with other reports indicat-
ing that, like p125FAK, activation of CADTK is dependent on
the integrity of the actin cytoskeleton (24, 25, 27). In contrast,
the pervanadate-stimulated CADTK phosphorylation was not
inhibited by cytochalasin D, suggesting that this treatment
disrupted the factor (or factors) required for agonist-dependent
activation of CADTK. Although previous studies have not
clearly established the intracellular localization of CADTK, our
studies now suggest the importance of actin filament associa-
tion. Using transient overexpression systems (COS), Sasaki
and co-workers (15) had reported that CADTK/Cakb was found
in areas of cell-cell contact. Instead, Li et al. (19) suggested
co-localization of RAFTK/CADTK with vinculin and focal ad-
hesion-like structures in COS or CMK megakaryocytes. Our
studies support the localization of CADTK to the cytoskeleton,
and we find immunostaining on actin filaments (stress fibers)
that extends into the focal adhesions in RSMC. This is clearly
distinct from p125FAK or viculin, which are restricted to focal
adhesions in these cells.5 It is important to emphasize that we
examined the immunofluorescence of endogenous CADTK in
RSMC rather than in cells over-expressing artificially high
levels of CADTK that may result in additional or aberrant sites
of localization. Taken together, the ability of CADTK to phos-
phorylate paxillin, the inhibition of CADTK by cytochalasin D,
and the focal adhesion and actin localization all point to an
important role for CADTK cytoskeletal signaling interactions.
Furthermore, despite a high amount of sequence homology and
some similarities in intracellular localization to p125FAK (focal
adhesions), we find important differences in the ability of ago-
nists (PDGF, Ang II) to regulate CADTK and p125FAK in these
cells. Whether or not the differential regulation of these kinases
is due to the expanded intracellular localization of CADTK or its
mechanism of activation remains to be determined.
The activation of CADTK by Ang II or PDGF is expected to
have an important influence on intracellular protein kinase
signaling pathways in smooth muscle cells. In GN4 rat liver
epithelial cells, activation of CADTK correlates with an in-
crease in the c-Jun NH2-terminal kinase (Jnk) activity,
whereas activation of CADTK does not parallel MAP kinase or
p90RSK activity in these cells (13, 22). Additional studies from
our laboratory have suggested that activation of CADTK may
also increase p70 S6 kinase signaling (22). This is contrasted
with PC12 cells, where the activation of CADTK (Pyk-2) corre-
lates with an increase in both MAP kinase and Jnk kinase
activities (14, 21).
In smooth muscle cells, Ang II and PDGF have been shown to
activate MAP kinase (37, 38), p70 S6 kinase (39), and Jnk (40),
and based on the earlier studies, we speculate that the latter
two may occur via a CADTK-stimulated pathway. For example,
thapsigargin increases both Jnk and p70 S6 kinase activity but
does not activate MAP kinase in RSMC.6 Activation of these
kinase signaling pathways may ultimately regulate the pro-
cesses of smooth muscle proliferation, migration, or hyperten-
sion, although the role of CADTK in these processes remains to
be established. In any event, because of its cytoskeletal associ-
ation and response to smooth muscle stimuli, CADTK is antic-
ipated to be an important mediator of signaling events that
influence smooth muscle physiology.
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